Episodios
-
Silke Gillessen joins Tom and Brian, who give their opinion on the data and new 'Take Home Message' format.
-
Nobuaki Matsubara, Hiroshi Kitamura and Yuji Miura battle through the sometimes ridiculous questions set by Tom and Brian.
-
¿Faltan episodios?
-
Guru Sonpavde describes the efficacy of chemotherapy with nivolumab in lymph node only 1st line UC patients. Tom describes the QOL data for EV pembro.
-
Laurence Albiges discusses this circulating biomarker which may be predictive and prognostic.
-
Andrea Necchi gives us the lowdown of efficacy and toxicity of this combination.
-
Jonathan Rosenberg gets to grips with the data available for the bladder cohort from the TDXD Destiny pan-tumour cohort.
-
Danny Heng, Christian Kollmannsberger and Kala Sridhar answer questions in an attempt to get to Nashville and take on LA to win the Uromigos Cup.
-
What to see at the ASCO 2024 Annual Meeting, with Silke Gillessen.
-
Nick James discusses this paper, which covers broad issues in prostate cancer - including diagnosis and treatment with a focus on the future.
-
David Penson discusses highlights for the upcoming meeting. He articulates his excitement around the NMIBC data.
-
Silke covers key aspects of the meeting, including surgery vs RT, genetic and somatic testing, PSMA imaging and 1st line triplet therapy.
-
Thomas Suter and Chuck Ryan discuss identification and management of cardiovascular disease for patients starting therapy for prostate cancer.
-
Thomas Zilli and Pierre Blanchard discuss this topic from Lugano.
-
Jason Efstathiou and Piet Ost discuss the data for and against this approach.
-
Alison Birtle describes adjuvant chemotherapy in bladder cancer.
- Mostrar más